Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 16:6:280.
doi: 10.12688/f1000research.10587.1. eCollection 2017.

Recent advances in managing and understanding uveitis

Shih-Chou Chen  1 , Shwu-Jiuan Sheu  2
Affiliations
Review

Recent advances in managing and understanding uveitis

Shih-Chou Chen et al. F1000Res. .

Abstract

Uveitis is a sight-threatening disease entity with intraocular inflammation that arises from various causes. It mainly affects working-age individuals and may lead to irreversible visual loss if not treated properly in a timely manner. This article reviews recent advances in the management and understanding of uveitis since 2014, including treatment with new immunosuppressive therapies that use biological agents, local therapy with steroid implants, and imaging studies for the evaluation of uveitis.

Keywords: immunosuppressive therapy; ocular implants; optical coherence tomography (OCT); uveitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests. The authors alone are responsible for the content and writing of the article.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. : Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–6. 10.1136/bjo.80.4.332 - DOI - PMC - PubMed
    1. Suttorp-Schulten MS, Rothova A: The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–8. 10.1136/bjo.80.9.844 - DOI - PMC - PubMed
    1. Chang JH, Wakefield D: Uveitis: a global perspective. Ocul Immunol Inflamm. 2002;10(4):263–79. 10.1076/ocii.10.4.263.15592 - DOI - PubMed
    1. Merida S, Palacios E, Navea A, et al. : New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci. 2015;16(8):18778–95. 10.3390/ijms160818778 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Levy-Clarke G, Jabs DA, Read RW, et al. : Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3. 10.1016/j.ophtha.2013.09.048 - DOI - PubMed

    2. F1000 Recommendation

LinkOut - more resources